^
BIOMARKER:

CDK12 mutation

i
Other names: CDK12, Cyclin Dependent Kinase 12, Cdc2-Related Kinase, Arginine/Serine-Rich, Cell Division Cycle 2-Related Protein Kinase 7, Cell Division Protein Kinase 12, CDC2-Related Protein Kinase 7, Cyclin-Dependent Kinase 12, CRKRS, CRK7, CDC2 Related Protein Kinase 7, HCDK12, CrkRS, CRKR
Entrez ID:
Related biomarkers:
CDK12 mutation
Prostate Cancer
olaparib
Sensitive: A2 - Guideline
CDK12 mutation
Ovarian Cancer
olaparib
Sensitive: B - Late Trials
CDK12 mutation
Prostate Cancer
nivolumab
Sensitive: C2 – Inclusion Criteria
CDK12 mutation
HER2 Negative Breast Cancer
durvalumab
Sensitive: C2 – Inclusion Criteria
CDK12 mutation
Prostate Cancer
pembrolizumab
Sensitive: C3 – Early Trials
CDK12 mutation
Prostate Cancer
AST-2970
Resistant: C3 – Early Trials
CDK12 mutation
Prostate Cancer
enzalutamide
Resistant: C3 – Early Trials
CDK12 mutation
Prostate Cancer
rucaparib
Resistant: C3 – Early Trials
CDK12 mutation
Breast Cancer
olaparib
Sensitive: C3 – Early Trials
CDK12 mutation
Prostate Cancer
GnRH stimulant
Resistant: C3 – Early Trials
CDK12 mutation
Prostate Cancer
Immunotherapy
Resistant: C3 – Early Trials
CDK12 mutation
Prostate Cancer
enzalutamide + abiraterone acetate
Resistant: C3 – Early Trials
CDK12 mutation
NSCLC
olaparib
Sensitive: C4 – Case Studies
CDK12 mutation
Prostate Cancer
nivolumab + ipilimumab
Sensitive: C4 – Case Studies